Theravance Biopharma Inc

0TB

Company Profile

  • Business description

    Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

  • Contact

    Ugland House, South Church Street
    George Town, PO Box 309
    Grand CaymanKY1-1104
    CYM

    T: +1 650 808-6000

    E: [email protected]

    https://www.theravance.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    99

Stocks News & Analysis

stocks

Best and worst performing ASX sectors of 2024

Exploring the ASX sectors that moved the market this year.
stocks

2 ASX companies with the traits of a long-term winner

Two companies that show promising signs of handsomely rewarding shareholders.
video

Our outlook for 2025

Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,316.7098.30-1.17%
CAC 407,274.4819.89-0.27%
DAX 4019,884.7585.11-0.43%
Dow JONES (US)42,840.26498.021.18%
FTSE 1008,084.6120.71-0.26%
HKSE19,720.7031.81-0.16%
NASDAQ19,572.60199.831.03%
Nikkei 22538,701.90111.68-0.29%
NZX 50 Index12,904.11149.961.18%
S&P 5005,930.8563.771.09%
S&P/ASX 2008,067.00101.20-1.24%
SSE Composite Index3,368.071.96-0.06%

Market Movers